Soluble guanylyl cyclase (sGC) plays a crucial role in cyclic nucleotide signaling that regulates numerous important physiological processes. To identify new sGC inhibitors that may prevent the formation of the active catalytic domain conformation, we carried out an in silico docking screen targeting a 'backside pocket' of the inactive sGC catalytic domain structure. Compounds 1 and 2 were discovered to inhibit sGC even at high/saturating nitric oxide concentrations. Both compounds also inhibit the BAY 58-2667-activated sGC as well as BAY 41-2272-stimulated sGC activity. Additional biochemical analyses showed that compound 2 also inhibits the isolated catalytic domain, thus demonstrating functional binding to this domain. Both compounds have micromolar affinity for sGC and are potential leads to develop more potent sGC inhibitors.
Keywords: enzyme inhibition; soluble guanylyl cyclase Soluble guanylyl cyclase (sGC) is the main mammalian receptor for the gaseous signaling molecule nitric oxide (NO) [1, 2] . Binding of NO to sGC augments the production of cGMP by several hundred fold [3] [4] [5] . cGMP is an important second messenger molecule in cells and binds to protein kinase G, ion channels, and phosphodiesterases [6] . This regulation by cGMP leads to various physiological responses including vasodilation, photosensitivity, and cell growth and differentiation [7] .
Soluble guanylyl cyclase (sGC) is a heterodimeric enzyme comprised of four domains: the HNOX, PAS, coiled-coil, and catalytic guanylyl cyclase domains. Structures of individual domains from sGC or from bacterial homologs have been solved [8] [9] [10] [11] [12] [13] [14] [15] . The precise signal transduction events required for activation are not known although some insight has been gained from low-resolution structural studies [16, 17] .
In contrast to pharmaceutical activation of sGC [18] , targeting inhibition of sGC is less well explored. In diseases such as sepsis and cancer, inhibition of sGC could potentially be beneficial [19] [20] [21] . For example, time-dependent inhibition of sGC improves bactericidal activity, restores vasoconstriction in sepsis, and reduces mortality in both a rat sepsis model and mouse model [19, 20] although the opposite strategy, that is, activating sGC, was beneficial in a different study [22] . Inhibition of the cGMP/sGC pathway decreases tumor cell migration and invasion [21, 23] , whereas stimulating of this pathway does the opposite for invasion of melanoma cells [24] . Furthermore, inhibition of sGC decreases angiogenesis [25, 26] which could also aid in cancer treatment [23, 24, 26] . In addition, inhibition of sGC attenuates dysfunctions in basal ganglia in Parkinson's disease, by reversing many molecular dysfunctions in the murine nervous system [27] .
The most commonly used sGC inhibitors, ODQ and NS2028, are effective both in vitro and in vivo. These inhibitors are similar in structure and decrease sGC activity by oxidizing the heme cofactor in the regulatory H-NOX domain of the b1 subunit of the enzyme (potentially resulting in heme loss). Due to this mechanism of inhibition, these compounds are unlikely to affect basal sGC activity, and indeed ODQ was found to be effective in inhibiting only NO-activated sGC activity [28] and ODQ inhibition can be overcome by increasing the concentration of NO [29] . ODQ may not be sGC specific as it can also act on other hemecontaining molecules like hemoglobin [30] . These observations suggest the need for new inhibitors of sGC, especially compounds that can attenuate enzymatic function independent of allosteric activation.
Candidate target sites most useful for identifying activation-independent inhibitors of sGC are most likely to reside in the catalytic cyclase domain. Crystal structures of both a wild-type and a mutated inactive catalytic domain of human sGC have been solved both in an inactive conformation [14, 15] . These structures suggest that upon sGC activation, the catalytic domain undergoes a conformational change via a 26°rotation of the a1 subunit of the catalytic domain [15] . Although not in an active conformation, we reasoned that the sGC catalytic domain crystal structure could be used to target the dimer interface for binding of small molecules to act as allosteric inhibitors and prevent the interdomain reorientation needed for activation. The crystal structure of the catalytic domain reveals a partially occluded active site, as well as a pocket on the other side of the heterodimer which we term a 'backside pocket' (Fig. 1 ). This backside pocket at the dimer interface could be used to develop allosteric inhibitors, since a small molecule bound there is likely to prevent reorienting of the two interfaces thereby locking the catalytic domains in an inactive conformation.
Here, we used in silico docking screening with the University of Cincinnati compound library to identify compounds that could potentially bind to this backside pocket site, and characterized the matches biochemically. Our efforts serve dual purposes: the first is to probe the hypothesized rotational catalytic domain activation mechanism, as successfully inhibiting sGC in this manner would provide evidence for such a mechanism; the second is to discover new lead compounds that could be developed into a potent new class of sGC inhibitors that affect both the NO stimulated and basal sGC activities. Such compounds could serve as molecular tools to probe sGC function and also have therapeutic potential.
Materials and methods

In silico compound screening
The GLIDE/SCHRODINGER software package [31] was used for docking the compounds of the University of Cincinnati compound database (~350 000 compounds). We used an inactive mutant human catalytic domain structure (PDB ID 3UVJ) as the target for our initial computational screens, as that was the only structure of the catalytic domain available at the time. We choose a 14 9 14 9 14 A outer box in the catalytic domain region near b1 residues S541 and T474 (both side chain hydroxyl moieties were kept fixed) for the docking, and used default settings for the HTVS, SP, and XP (extraprecision) docking searches. The compounds identified were obtained from the University of Cincinnati (compounds 1-4 with IDs #AF-407/12044005, #5192950, #384033, and #5141573, respectively). Additional quantities of compounds 1, 2, and 4 were subsequently purchased from Specs and Chembridge.
Expression and purification of sGC catalytic domain
The vectors for wild-type catalytic domain expression were obtained from the Structural Genomics Consortium (SGC). The individual subunits were expressed and purified as previously described [15] . In short, the heterodimeric protein was prepared by mixing together cell pellets containing either the expressed b1 or a1 catalytic domain, and resuspension in 50 mM sodium phosphate pH 7.5, 500 mM NaCl, and 30 mM imidazole. Cells were lysed using a microfluidizer followed by centrifugation of the lysate at 20 000 g for 1 h. The supernatant was applied to Ni-nitrilotriacetic acid beads (Qiagen, Valencia, CA, USA) preequilibrated with the cell lysis buffer. The beads were washed with 50 mM sodium phosphate pH 7.5, 500 mM NaCl, and 60 mM imidazole and the protein eluted with a similar buffer containing 300 mM imidazole. The His tag was subsequently cleaved overnight with TEV protease in 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% ethylene glycol, and 1 mM TCEP. After cleavage, the protein was loaded onto a Superdex 200 column (GE Life Sciences, Pittsburgh, PA, USA) pre-equilibrated with 50 mM HEPES pH 7 and 150 mM NaCl. The fractions containing the protein were pooled and stored at À80°C. Aliquots were thawed for activity assays and other experiments.
Activity measurements
We measured NO-stimulated sGC activitiy using bovine lung sGC (Enzo Life Sciences, Farmingdale, NY, USA). sGC was diluted 17-fold in 50 mM Tris pH 7.5, 5 mM MgCl 2 , 2 mM b-mercaptoethanol (BME), 20% sucrose, and 0.5 mgÁmL À1 BSA. We preincubated sGC (1 nM final enzyme concentration) with varying concentrations of each inhibitor in 50 mM Tris pH 7.5, 2 mM BME, and 5 mM MgCl 2 for 10 min at 37°C. The uninhibited sGC activity was measured in the presence of 1-2.5% DMSO as a control to match the DMSO concentrations present in the inhibitor experiments due to the DMSO in the inhibitor stock solutions. The NO-stimulated sGC reaction was initiated by the addition of varying concentrations of GTP in the presence of 100 lM of the NO donor S-nitroso-N-acetylpenicillamine (SNAP), and continued for 10 min at 37°C before boiling the sample for 10 min to stop the reaction. The activity assays with heme independent activator BAY The terminal primary amine group of a K524 was not present in the structure of the catalytic domain (3UVJ), but was modeled in this figure as it can potentially form an interaction with chloride atom of compound 2. Similarly, the side chain of E473 was not included in the crystal structure but added here for illustrative purposes (this side chain is not anticipated to interact with either of the compounds). All the backside pocket residues are conserved in bovine and human sGC.
58-2667 were done using varying concentrations of BAY 58-2667 with 100 lM inhibitor. About 1 nM of bovine lung sGC was incubated with both BAY 58-2667 and inhibitors for 10 min at 37°C in the presence of 5 mM MgCl 2 . The reaction was started by addition of 600 lM GTP. The activity assays with the sGC stimulator BAY 41-2272 were done using varying concentrations of BAY 41-2272 (both in the presence and absence of the NO donor SNAP) with 100 lM of compound 1 or 2 in the presence of 5 mM MgCl 2 . About 1 nM bovine lung sGC was preincubated with different compounds and BAY 41-2272 for 10 min at 37°C. The reaction was started by the addition of 500 lM GTP and after 10 min was stopped by boiling. The catalytic domain activity assays utilized 1 lM final concentration of purified catalytic domain. The inhibitors were preincubated with the catalytic domain for 10 min at 37°C in the presence of Mg 2+ . The reaction was started by the addition of GTP, and stopped after 10 min by boiling. All above cyclase reactions were repeated in three independent experiments. The cGMP generated was measured using an ELISA (EIA) kit (Cayman Chemical, Ann Arbor, MI, USA).
Analysis of sGC inhibition
The inhibition data from NO-activated full-length sGC activity assays were fit using GRAPHPAD PRISM 6 software (La Jolla, CA, USA). The models were fit individually in a noncompetitive inhibition mode, competitive inhibition mode, and mixed inhibition mode. The goodness of fit was examined by the R-squared value in each mode. The data were interpreted using a mixed model of inhibition and the value of a. The K i was determined by fitting the data to the mode of inhibition suggested by the value of a.
Results
In silico screening
An initial docking screen yielded~30 compounds predicted to bind to several sites along the dimer interface including the backside pocket. The active site and the backside pocket are on opposite sides of the dimer, yet they are proximal as both the active site and backside pocket are quite deep and approach each other near the middle of the heterodimeric catalytic domain (Fig. 1A, B, C) . Nonetheless, the two pockets are separated by a short section of residues including residue T527. We chose molecules that yielded promising docking scores for their relatively small (fragment-like) size to use as lead compounds. The structures of the initial lead compounds 1 and 2 and their computationally docked binding mode to the catalytic domain are shown in Fig. 1D , E. From our inspection of the molecular docking of inhibitors and the catalytic domain, compound 1 forms hydrogen bonds with the side chain and/or main chain atoms of a1 T527, a1 G529, a1 K524, and b1 L542 and b1 E473. In addition, the phenyl moiety of compound 1 makes van der Waals interactions with a1 Y510 and Y532, and b1 I533 and F543 (Fig. 1E) . Compound 2 is docked in the same site and hydrogen bonds to side chain and/or main chain atoms of residues b1 S541, b1 L542, b1 T474, and a1 G529, and forms van der Waals interactions with a1 Y510, a1 I528, a1 Y532, b1 I533, and b1 F543. For both inhibitors, most of the ligand-protein interactions are predicted to be with the peptide backbone. We obtained the initial compounds from the University of Cincinnati as 10 mM stock solutions in DMSO. These compounds were tested for inhibition in vitro using reactions containing 1 nM bovine lung sGC, 25 lM GTP, 100 lM SNAP, and 10 lM inhibitor. After this initial screen, compounds 1 and 2 yielded substantial inhibition of NO-stimulated sGC activity (Fig. 2) . We subsequently searched the University of Cincinnati compound database for analogs, resulting in the identification of compounds 3 and 4 ( Fig. 1) . Compounds 3 and 4 ( Fig. 1D ) were obtained to test whether variation in the structures of compounds 1 and 2 might improve or decrease inhibition of sGC in a manner consistent with chemical specificity in their mode of action. Compound 3 has an additional methyl group at the C6 position compared to compound 2. The compound 1 analog, compound 4, has the same 6-azacytosine moiety but with a carboxyphenol ribose moiety attached to a different ring-nitrogen. Upon testing, both compounds 3 and 4 demonstrated inhibition of sGC, although the observed inhibition was significantly weaker compared to compounds 1 and 2 (Fig. 2) .
Testing for inhibition by nonspecific inhibition/ aggregation
We tested compounds 1 and 2 for undesired, promiscuous inhibition, a behavior often observed for hits from compound libraries [32] [33] [34] . We first tested the unrelated enzyme lactate dehydrogenase (LDH) and found that none of the compounds inhibited LDH (Fig. 3) . In addition, we probed the unrelated enzymes SHV-1 b-lactamase and b-galactosidase (Fig. S1) . Compound 2 showed no inhibition of b-lactamase or b-galactosidase (Fig. S1 ). Compound 1 also did not inhibit SHV-1 b-lactamase (Fig. S1 ); we were, however, unable to test compound 1 with b-galactosidase because its intrinsic absorption interfered with the spectroscopic assay. Next, we tested whether compounds 1 and 2 could form aggregates using a dynamic light scattering device (DYNAPRO) as this provides a means of identifying promiscuous aggregators which can cause loss of protein function [35, 36] . The results show that the inhibitors do not form detectably large aggregates (Fig. S2) . We also used size exclusion chromatography with full-length sGC and 200 lM concentrations of compounds 1 and 2 to confirm that the inhibitors did not cause sGC aggregation (data not shown). As a final quality control method, we confirmed the purity of all purchased compounds using LC-MS to check their chemical integrity (Fig. S3) . The molecular weights matched the calculated molecular weights and combined with the Chembridge and Specs-supplied NMR spectra, indicate the correct chemical composition of the compounds. The above experiments confirm that compounds 1 and 2 bind with chemical specificity to inhibit sGC activity and are not promiscuous inhibitors.
Inhibition of sGC is independent of NO activation
To gain additional insight into the mechanism of sGC inhibition we tested the ability of compounds 1 and 2 to inhibit sGC that was activated by the NO-independent activator BAY 58-2667. The data in Fig. 4 show that 100 lM of compound 1 or 2 inhibited BAY 58-2668-activated sGC by 96% and 99%, respectively. These results indicate that the inhibitors act by a different mechanism than inhibitors such as ODQ, which do not inhibit sGC that is activated by BAY 58-2667. Note that their analogs, compounds 3 and 4, showed only modest inhibition at only the lowest BAY 58-2667 concentration (Fig. 4) . To probe whether compounds 1 and 2 could inhibit NO-dependent sGC stimulation by BAY 41-2272, we tested a range of BAY 41-2272 concentrations in the presence and absence of a low (1 lM) concentration of NO (Fig. 4) . Similar to inhibiting BAY 58-2667-activated sGC, compounds 1 and 2 also inhibited BAY 41-2272-stimulated sGC.
Analysis of inhibition mechanism using steady-state kinetics
Steady-state kinetics were used to probe the inhibitory mechanism of compounds 1 and 2. Reactions contained 1 nM full-length bovine lung sGC in the presence of 100 lM SNAP with varying substrate and inhibitor concentrations (Fig. 5) . The matrix of steadystate kinetic data was globally fit to different models of steady-state inhibition to identify the mechanism of inhibition and estimate the apparent K i for these compounds. The goodness of fit, measured with the nonlinear R-squared value for the global fit for each curve was > 80% for each inhibitor (Fig. S4) . We observed that the K i for each inhibitor determined on different days was subject to contributions to experimental error from variation in V max likely due to differences in enzyme specific activity. Accordingly, relative measurements were analyzed using parallel control reactions in the absence of inhibitor. Additionally, to further reduce experimental error it was necessary to optimize the activity assays for presence of BME and BSA in the sGC dilution buffer and the activity buffer (Fig. S5) . Reactions at the highest concentrations of inhibitor were limited by low signal to noise and enzyme stability due to the long incubation times required to observe product formation. Data at > 100 lM compound 1 and 2 were collected but excluded from the global fitting since they contained a proportionally higher level of experimental error due to these limitations. Although only a relatively narrow range of rate constants are accessible using standard ELISA assays for sGC activity, the data nonetheless show that compounds 1 and 2 inhibit SNAP-activated sGC activity at micromolar concentrations.
In order to test for different mechanisms of inhibition, the reaction velocities observed over a range of inhibitor and substrate concentrations were globally fit to mixed model of inhibition represented by the following equilibrium reaction scheme:
In this general mechanism, the inhibitor can bind both to the free enzyme as well as the enzyme-substrate complex with varying affinities and behaves according to the following rate equation: 
In this expression the affinity of the inhibitor for the free enzyme is defined as K i . The magnitude of the term a allows the inhibition mechanism to be evaluated. When a approaches 1, the inhibitor is defined as noncompetitive, whereas when a approaches infinity the mechanism becomes competitive. When the steadystate inhibition data were globally fit to the above equation, the a-value for compound 1 was 3.6. In contrast, the a-value for compound 2 was very high (3.0 9 10 24 ). The magnitude of these values suggest a mostly noncompetitive inhibition mechanism for compound 1 with a moderately higher affinity for the E.S complex (a > 1). However, a competitive inhibition mechanism is indicated for compound 2 (a ≫ 1).
Both compound 1 and 2 provided inhibition of SNAP-activated sGC activity at micromolar concentrations (Fig. 5A,B) . The observed K i values for compounds 1 and 2, assuming noncompetitive inhibition for compound 1 and competitive inhibition for compound 2, were 28 AE 11 lM and 19 AE 5 lM, respectively. The calculated K i for compounds 3 and 4 indicated that they were weaker inhibitors (284 AE 85 lM and 193 AE 56 lM, respectively) ( Figs S4 and S6) . Overall, the steady-state kinetics indicate that compounds 1 and 2 function as the best inhibitors and they provide inhibition of SNAPactivated sGC in the micromolar range, albeit by different mechanisms. 
Probing inhibition with the catalytic domain
We next tested whether compounds 1 and 2 could inhibit the purified catalytic domain since this domain contains the targeted site used for in silico screening. We note that the activity of the purified catalytic domain by itself was much weaker than the full-length sGC as was previously observed by others [14] . We tested the inhibition of 1 lM catalytic domain at three different GTP substrate concentrations and varied the inhibitor concentrations from 0 to 600 lM. Only compound 2 showed inhibition at the higher inhibitor concentrations with > 50% inhibition of the purified catalytic domain at 400 lM compound 2 (Fig. 6) . In contrast to compound 2, we did not observe significant inhibition with compound 1, even up to 600 lM concentration of compound 1 (Fig. 6) . Compounds 3 and 4 did not significantly inhibit the catalytic domain (Fig. S7 ) although compound 4's inhibition profile was similar to that of compound 2.
Discussion
We set out to develop allosteric inhibitors directed against the catalytic domain of sGC with the goal of probing the rotational catalytic domain conformational activation mechanism as well as developing a novel inhibitor tool that can be used to probe sGC basal and stimulated activity functions in vitro. The data shown here identify two molecules described that inhibit SNAP-activated sGC at micromolar concentrations (27 AE 11 lM and 19 AE 5 lM for compounds 1 and 2, respectively).
Our hypothesis is that these inhibitors bind to the backside pocket of the sGC catalytic domain, as targeted and predicted by in silico docking. In this model the compounds can bind to free E or the E.S complex, ultimately preventing the formation of the active conformation of the catalytic domain making this pocket an allosteric site for the development of inhibitors. This perspective is supported by the following observations. When the inhibition data were fitted to a mixedinhibition model, to probe for either competitive or noncompetitive inhibition, the a-value for compound 1 was relatively close to 1, while that of compound 2 was very high. This indicates that compound 2 likely inhibits sGC in a mostly competitive manner, whereas compound 1 is likely to be predominantly a noncompetitive inhibitor and preferentially binds the sGC-GTP complex. It is also possible that compound 1 captures sGC between a completely activated state and a completely inactivated state, where the binding of GTP to the active site is reduced. Furthermore, both inhibitors decrease BAY 58-5667-stimulated sGC activity by > 90%, suggesting that both compounds do not merely inhibit sGC by inactivating NO/SNAP or interfering with the heme redox state. In addition, both inhibitors also inhibit BAY 41-2272-stimulated sGC activity. BAY 41-2272 stimulation of sGC occurs via a different mechanism, compared to BAY 58-2276, that is not yet fully understood, yet does require low concentrations of NO either added or already present in the environment [37] . BAY 41-2272, or its analog YC-1, is postulated to bind to either the b1 chain near or in the H-NOX domain [38] or to the catalytic domain [37, 39] . That compounds 1 and 2 inhibit both BAY 58-2276-activated sGC and BAY 41-2272-stimulated sGC suggest that compounds 1 and 2 act on a common part of these different activation/stimulation mechanisms; this is consistent with compounds 1 and 2 acting on the catalytic domain.
Additional evidence for the compounds targeting the catalytic domain, at least for compound 2, comes from assays with the purified catalytic domain which showed that, unlike compound 1, compound 2 does inhibit catalytic domain activity (Fig. 6) . However, this compound 2 inhibition occurs at higher concentrations than required for its inhibition of SNAP-activated, full-length sGC. We do not have an explanation for this observation except to note that the catalytic domain sGC heterodimer is likely not a uniform oligomeric mixture as previously observed [14] . Note also that we used a 1 lM catalytic domain concentration for our assay, which is below the dimerization constant of heterodimers [14] and suggests a predominance of inactive monomers in solution. However, the addition of GTP and Mg 2+ has been shown to shift the catalytic dimerization constant to 0.45 lM [40] indicating that at the concentrations we used to measure activity, the subunits may mostly be in a dimer state.
We next carried out a similarity search to find molecules that were similar to compounds 1 and 2 to gain additional insight into which chemical moieties are important for activity. We found one analog for each that did exhibit inhibition of SNAP stimulated sGC, albeit with a weaker affinity. The compound 2 analog, compound 3, yielded K i values of 284 AE 85 lM, whereas the compound 1 analog, compound 4, had a K i of 193 AE 56 lM. We speculate that the weaker affinity of compound 3, compared to compound 2, might be due to unfavorably burying a hydrogen bond donor (i.e., carbonyl oxygen of a1 T527) upon addition of the methyl group at the C6 position of the tetrahydropyran ring. The analog of compound 1, compound 4, has an additional ribose ring connected to the azacytosine ring. The ribose group contains an ester of benzoic acid at the 5 0 carbon. Compound 4 is considerably larger than compound 1, and we speculate that the steric hindrance could decrease binding to the catalytic domain. Furthermore, the ribose sugar moiety branches off from the azacytosine-nitrogen that is involved in hydrogen bonding with b1 E473 in compound 1. This may considerably reorient the inhibitor compared to compound 1 and could also explain the lower affinity.
Unlike the original compounds, compounds 3 and 4 do not cause inhibition of BAY 58-2667 activated sGC, at high BAY 58-2667 concentrations. However, at the lowest concentration of BAY 58-2667 (0.1 nM), these analogs did show a modest inhibition in sGC activity: a 38% decrease in activity for compound 3, and 24% for compound 4 (Fig. 4) . Furthermore, we observed that our analogs did not inhibit purified catalytic domain, even up to 1 mM inhibitor concentration. Overall, these results highlight chemical specificity of the compounds 1 and 2 for sGC inhibition.
Compound 2 is the most promising lead because of its highest affinity and its ability to inhibit full-length sGC activated by either SNAP, BAY 58-2667, or BAY 41-2272 as well as purified sGC catalytic domain. Compound 2 behaves mostly as a competitive inhibitor, as judged by its a value. This suggests that compound 2 does not bind to sGC when bound to GTP, and thus that binding of compound 2 to the backside pocket prevents binding of GTP. However, since we do not have direct evidence that compound 2 binds in the backside pocket of the catalytic domain, it is also possible that compound 2 can bind to the active site and compete with GTP for its binding site. We have also ruled out other nonspecific modes of inhibition, for example, via promiscuous inhibition, by testing the effect of all compounds on several unrelated enzymes. Despite our promising in vitro results, none of the compounds provided inhibition of sGC activity in transiently transfected COS7 cells when tested up to 100 lM concentrations (data not shown). Therefore, these compounds need to be improved in terms of affinity and possibly also cell permeability and/or stability. Nevertheless, these molecules could serve as lead molecules for iterative drug design to develop new sGC inhibitors. While preparing this manuscript, a similar approach to target the catalytic domain was also published [41] . 
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